Shilong Zhang

6PUBLICATIONS
5CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Nutritional epidemiologyInnate immunityPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 25, 2024
Acarbose enhances the efficacy of immunotherapy against solid tumours by modulating the gut microbiota.

Shi-Long Zhang, Xin Wang, Qing-Qing Cai

|Mar 29, 2023
Early Administration of Vancomycin Inhibits Pulmonary Embolism by Remodeling Gut Microbiota.

Zhengyan Zhang, Huiling Chen, Jiating Huang

|Mar 08, 2022
Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice.

Shi-Long Zhang, Bing Han, Yu-Qin Mao

|Sep 21, 2020
Sulfiredoxin-1 is a promising novel prognostic biomarker for hepatocellular carcinoma.

Qian-Wen Rao, Shi-Long Zhang, Meng-Zhou Guo

|Mar 18, 2020
Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.

Zhi-Ming Wang, Shi-Long Zhang, Hua Yang

|Jan 11, 2019
Marital status and survival in patients with soft tissue sarcoma: A population-based, propensity-matched study.

Shi-Long Zhang, Wen-Rong Wang, Ze-Juan Liu

Pageof 1

Frequent Collaborators

1 joint publications

Jing-Lin Xia

1 joint publications

Qing-An Jia

1 joint publications

Yan Wang

1 joint publications

Zhi-Ming Wang